U.S. Markets open in 4 hrs 50 mins
S&P Futures
2,505.00
+0.25 (+0.01%)Dow Futures
22,341.00
+5.00 (+0.02%)
| Previous Close | 42.780 |
| Open | 42.800 |
| Bid | 39.020 x 100 |
| Ask | 0.000 x 0 |
| Day's Range | 42.090 - 42.800 |
| 52 Week Range | 36.580 - 47.100 |
| Volume | 58,582 |
| Avg. Volume | 95,126 |
| Net Assets | 450.55M |
| NAV | 42.91 |
| PE Ratio (TTM) | N/A |
| Yield | 0.61% |
| YTD Return | 10.07% |
| Beta (3y) | 1.16 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2006-06-19 |
- Barrons.com•12 hours ago
ETF Flopper: Repeal and Replace Revived, Sinks Health-Care Stocks
Health-care stocks finished dead last in the Standard & Poor's 500 as Republicans tried yet again to repeal and replace the Affordable Care Act. The Cassidy-Graham bill, named for Senator Bill Cassidy, R-La., and Lindsey Graham, R-S.C., was introduced Sept. 13 and appears to be gaining momentum. Cassidy-Graham would get rid of individual and employer mandates and subsidies and rollback Medicaid, among other things.
- Market Realist•9 days ago
Introducing Merck’s 2Q17 Immuno-Oncology Blockbuster
For 2Q17, Keytruda reported revenues of $881 million, which represents 183% growth at constant exchange rates.
- Market Realist•16 days ago
Eli Lilly’s Cardiovascular Products in 2Q17
Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company's total revenues.
